StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Sunday. The brokerage set a “sell” rating on the stock.

Bio-Path Trading Down 1.0 %

Shares of BPTH opened at $0.18 on Friday. The business’s fifty day moving average price is $0.75 and its two-hundred day moving average price is $0.89. Bio-Path has a 52 week low of $0.12 and a 52 week high of $7.67.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.